Genzyme, a Sanofi company, announced today that Health Canada has approved Aubagio® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
"There are many patients who simply cannot tolerate injections and have had no simple, effective, once daily oral medication until now," said Dr. Mark Freedman, Director, Multiple Sclerosis Research Unit and Professor of Neurology and Senior Scientist at the University of Ottawa and Ottawa Hospital Research Institute. "As a new oral treatment option, Aubagio is an important advancement for the MS community and may help improve quality of life for people living with this debilitating disease........ " Read More - http://www.ms-uk.org/aubagio
Oral MS treatment Aubagio® approved for RRMS in Canada
Oral MS treatment Aubagio® approved for RRMS in Canada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1030 Views
-
Last post by frodo
-
- 0 Replies
- 1649 Views
-
Last post by NHE
-
- 0 Replies
- 686 Views
-
Last post by DIM
-
- 0 Replies
- 2391 Views
-
Last post by NHE
-
- 1 Replies
- 1128 Views
-
Last post by Petr75
-
- 5 Replies
- 2390 Views
-
Last post by Jaded
-
- 0 Replies
- 4279 Views
-
Last post by NHE
-
- 0 Replies
- 2110 Views
-
Last post by frodo
-
- 0 Replies
- 2362 Views
-
Last post by Cece